-- 据周一提交给香港交易所的文件显示，歌礼制药（HKG:1672）宣布，其口服药物ASC30在美国的二期临床试验已完成患者招募。 该公司将开展为期13周的研究，以评估该药物作为2型糖尿病治疗药物的疗效。歌礼制药预计，该研究的主要数据将于2026年第三季度公布。 ASC30目前也在开发用于治疗肥胖症。
Related Articles
International
Ifo: German Export Morale Inches Up in April
German exporters turned slightly optimistic in April, while the overall sector moved neither forward nor backward due to geopolitical uncertainty, the ifo Institute said Monday.The ifo export expectations indicator increased to 0.1 point in April, from -0.7 points in March, as positive expectations roughly offset negative ones.Across the board, the export outlook for the automotive industry, electronics sector, and furniture manufacturers declined but remained generally positive. Expectations for shipments of food and beverages increased "significantly," while energy-intensive businesses forecasted lower exports.
$^SXXP
Mining & Metals
Big Banc Split to Complete Class A Share Split
Big Banc Split (BNK.TO) intends to complete a stock split of its Class A shares, citing strong performance of the shares, the fund said late on Friday.Class A shareholders of record at the close of business on May 1 will receive 20 additional Class A shares for every 100 Class A shares held.At completion of the share split, the Class A shares are expected to begin trading on an ex-split basis at the opening of trading on May 4.The preferred shares of the fund will not be affected and are expected to have downside protection from a decline in the value of the fund's portfolio of about 60%.Class A unitholders will continue to receive regular monthly non-cumulative cash distributions initially in the amount of $0.12 per Class A share, or $1.44 per year, following the Share Split. As a result, the total dollar amount of distributions to be paid to the holders of Class A shares is expected to increase by about 20%.The share split is subject to the approval of the Toronto Stock Exchange.
$BNK.TO
Japan